6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
1 O
% O
) O
are O
nausea O
, O
headache O
and O
vomiting O
( O
abdominal O
bloating O
, O
distension O
, O
pain/cramping O
, O
and O
watery O
diarrhea O
not O
requiring O
an O
intervention O
were O
not O
collected O
) O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Ferring O
at O
1-888-FERRING O
( O
1-888-337-7464 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
randomized O
, O
multicenter O
, O
controlled O
clinical O
trials O
, O
nausea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
vomiting B-OSE_Labeled_AE
were O
the O
most O
common O
adverse O
reactions O
( O
> O
1 O
% O
) O
following O
Prepopik O
( O
r O
) O
administration O
. O

The O
patients O
were O
not O
blinded O
to O
the O
study O
drug O
. O

Since O
abdominal B-OSE_Labeled_AE
bloating I-OSE_Labeled_AE
, O
distension B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
/ O
cramping B-OSE_Labeled_AE
, O
and O
watery B-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
are O
known O
to O
occur O
in O
response O
to O
colon O
cleansing O
preparations O
, O
these O
effects O
were O
documented O
as O
adverse O
events O
in O
the O
clinical O
trials O
only O
if O
they O
required O
medical O
intervention O
( O
such O
as O
a O
change O
in O
study O
drug O
or O
led O
to O
study O
discontinuation O
, O
therapeutic O
or O
diagnostic O
procedures O
, O
met O
the O
criteria O
for O
a O
serious O
adverse O
event O
) O
, O
or O
showed O
clinically O
significant O
worsening O
during O
the O
study O
that O
was O
not O
in O
the O
frame O
of O
the O
usual O
clinical O
course O
, O
as O
determined O
by O
the O
investigator O
. O

Prepopik O
( O
r O
) O
was O
compared O
for O
colon O
cleansing O
effectiveness O
with O
a O
preparation O
containing O
two O
liters O
( O
2L O
) O
of O
polyethylene O
glycol O
plus O
electrolytes O
solution O
( O
PEG O
+ O
E O
) O
and O
two O
5-mg O
bisacodyl O
tablets O
, O
all O
administered O
the O
day O
before O
the O
procedure O
. O

Table O
1 O
displays O
the O
most O
common O
adverse O
reactions O
in O
Study O
1 O
and O
Study O
2 O
for O
the O
Prepopik O
( O
r O
) O
Split-Dose O
and O
Day-Before O
dosing O
regimens O
, O
respectively O
, O
each O
as O
compared O
to O
the O
comparator O
preparation O
. O

Table O
1 O
: O
Treatment-Emergent O
Adverse O
Reactions O
observed O
in O
at O
Least O
( O
> O
1 O
% O
) O
of O
Patients O
using O
the O
Split-Dose O
Regimen O
and O
Day-Before O
Regimen O
abdominal B-NonOSE_AE
bloating I-NonOSE_AE
, O
distension B-NonOSE_AE
, O
pain B-NonOSE_AE
/cramping O
, O
and O
watery B-NonOSE_AE
diarrhea I-NonOSE_AE
not O
requiring O
an O
intervention O
were O
not O
collected O
Adverse O
Reaction O
Study O
1 O
: O
Split-Dose O
Regimen O
Study O
2 O
: O
Day-Before O
Regimen O
PREPOPIK O
( O
r O
) O
( O
N=305 O
) O
n O
( O
% O
= O
n/N O
) O
2L O
PEG+Ewith O
2 O
* O
5-mg O
bisacodyl O
tablets O
( O
N=298 O
) O
n O
( O
% O
= O
n/N O
) O
PREPOPIK O
( O
r O
) O
( O
N=296 O
) O
n O
( O
% O
= O
n/N O
) O
2L O
PEG+Ewith O
2 O
* O
5-mg O
bisacodyl O
tablets O
( O
N=302 O
) O
n O
( O
% O
= O
n/N O
) O
Nausea B-OSE_Labeled_AE
8 O
( O
2.6 O
) O
11 O
( O
3.7 O
) O
9 O
( O
3.0 O
) O
13 O
( O
4.3 O
) O
Headache B-OSE_Labeled_AE
5 O
( O
1.6 O
) O
5 O
( O
1.7 O
) O
8 O
( O
2.7 O
) O
5 O
( O
1.7 O
) O
Vomiting B-OSE_Labeled_AE
3 O
( O
1.0 O
) O
10 O
( O
3.4 O
) O
4 O
( O
1.4 O
) O
6 O
( O
2.0 O
) O
Electrolyte O
Abnormalities O
In O
general O
, O
Prepopik O
( O
r O
) O
was O
associated O
with O
numerically O
higher O
rates O
of O
abnormal B-OSE_Labeled_AE
electrolyte I-OSE_Labeled_AE
shifts O
on O
the O
day O
of O
colonoscopy O
compared O
to O
the O
preparation O
containing O
2L O
of O
PEG O
+ O
E O
plus O
two O
* O
5-mg O
bisacodyl O
tablets O
( O
Table O
2 O
) O
. O

These O
shifts O
were O
transient O
in O
nature O
and O
numerically O
similar O
between O
treatment O
arms O
at O
the O
Day O
30 O
visit O
. O

Table O
2 O
: O
Shifts O
from O
Normal O
Baseline O
to O
Outside O
the O
Normal O
Range O
at O
Day O
7 O
and O
Day O
30 O
Laboratory O
Parameter O
( O
direction O
of O
change O
) O
Visit O
Study O
1 O
: O
Split-Dose O
Regimen O
Study O
2 O
: O
Day-Before O
Regimen O
PREPOPIK O
( O
r O
) O
2L O
PEG+E O
with O
2* O
5 O
mg O
bisacodyl O
tablets O
PREPOPIK O
( O
r O
) O
2L O
PEG+E O
with O
2* O
5 O
mg O
bisacodyl O
tablets O
n/N O
( O
% O
) O
n/N O
( O
% O
) O
Potassium B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
19/260 O
( O
7.3 O
) O
11/268 O
( O
4.1 O
) O
13/274 O
( O
4.7 O
) O
13/271 O
( O
4.8 O
) O
24-48 O
hours O
3/302 O
( O
1.0 O
) O
2/294 O
( O
0.7 O
) O
3/287 O
( O
1.0 O
) O
5/292 O
( O
1.7 O
) O
Day O
7 O
11/285 O
( O
3.9 O
) O
8/279 O
( O
2.9 O
) O
6/276 O
( O
2.2 O
) O
14/278 O
( O
5.0 O
) O
Day O
30 O
11/284 O
( O
3.9 O
) O
8/278 O
( O
2.9 O
) O
7/275 O
( O
2.5 O
) O
8/284 O
( O
2.8 O
) O
Sodium B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
11/298 O
( O
3.7 O
) O
3/295 O
( O
1.0 O
) O
3/286 O
( O
1.0 O
) O
3/295 O
( O
1.0 O
) O
24-48 O
hours O
1/303 O
( O
0.3 O
) O
1/295 O
( O
0.3 O
) O
1/288 O
( O
0.3 O
) O
1/293 O
( O
0.3 O
) O
Day O
7 O
2/300 O
( O
0.7 O
) O
1/292 O
( O
0.3 O
) O
1/285 O
( O
0.4 O
) O
1/291 O
( O
0.3 O
) O
Day O
30 O
2/299 O
( O
0.7 O
) O
3/291 O
( O
1.0 O
) O
1/284 O
( O
0.4 O
) O
1/296 O
( O
0.3 O
) O
Chloride B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
11/301 O
( O
3.7 O
) O
1/298 O
( O
0.3 O
) O
3/287 O
( O
1.0 O
) O
0/297 O
( O
0.0 O
) O
24-48 O
hours O
1/303 O
( O
0.3 O
) O
0/295 O
( O
0.0 O
) O
2/288 O
( O
0.7 O
) O
0/293 O
( O
0.0 O
) O
Day O
7 O
1/303 O
( O
0.3 O
) O
3/295 O
( O
1.0 O
) O
0/285 O
( O
0.0 O
) O
0/293 O
( O
0.0 O
) O
Day O
30 O
2/302 O
( O
0.7 O
) O
3/294 O
( O
1.0 O
) O
0/285 O
( O
0.0 O
) O
0/298 O
( O
0.0 O
) O
Magnesium B-OSE_Labeled_AE
( I-OSE_Labeled_AE
high I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
34/294 O
( O
11.6 O
) O
0/294 O
( O
0.0 O
) O
25/288 O
( O
8.7 O
) O
1/289 O
( O
0.3 O
) O
24-48 O
hours O
0/303 O
( O
0.0 O
) O
0/295 O
( O
0.0 O
) O
0/288 O
( O
0.0 O
) O
0/293 O
( O
0.0 O
) O
Day O
7 O
0/297 O
( O
0.0 O
) O
1/291 O
( O
0.3 O
) O
1/286 O
( O
0.3 O
) O
1/285 O
( O
0.4 O
) O
Day O
30 O
1/296 O
( O
0.3 O
) O
2/290 O
( O
0.7 O
) O
0/286 O
( O
0.0 O
) O
0/290 O
( O
0.0 O
) O
Calcium B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
2/292 O
( O
0.7 O
) O
1/286 O
( O
0.3 O
) O
0/276 O
( O
0.0 O
) O
2/282 O
( O
0.7 O
) O
24-48 O
hours O
0/303 O
( O
0.0 O
) O
0/295 O
( O
0.0 O
) O
0/288 O
( O
0.0 O
) O
0/293 O
( O
0.0 O
) O
Day O
7 O
0/293 O
( O
0.0 O
) O
1/283 O
( O
0.4 O
) O
0/274 O
( O
0.0 O
) O
0/278 O
( O
0.0 O
) O
Day O
30 O
0/292 O
( O
0.0 O
) O
1/282 O
( O
0.4 O
) O
0/274 O
( O
0.0 O
) O
1/283 O
( O
0.4 O
) O
Creatinine B-OSE_Labeled_AE
( I-OSE_Labeled_AE
high I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
5/260 O
( O
1.9 O
) O
13/268 O
( O
4.9 O
) O
12/266 O
( O
4.5 O
) O
16/270 O
( O
5.9 O
) O
24-48 O
hours O
1/303 O
( O
0.3 O
) O
0/295 O
( O
0.0 O
) O
0/288 O
( O
0.0 O
) O
0/293 O
( O
0.0 O
) O
Day O
7 O
10/264 O
( O
0.4 O
) O
13/267 O
( O
4.8 O
) O
10/264 O
( O
3.8 O
) O
10/265 O
( O
3.8 O
) O
Day O
30 O
11/264 O
( O
4.2 O
) O
14/265 O
( O
5.3 O
) O
18/264 O
( O
6.8 O
) O
10/272 O
( O
3.7 O
) O
eGFR B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
22/221 O
( O
10.0 O
) O
17/214 O
( O
7.9 O
) O
26/199 O
( O
13.1 O
) O
25/224 O
( O
11.2 O
) O
24-48 O
hours O
76/303 O
( O
25.1 O
) O
72/295 O
( O
24.4 O
) O
82/288 O
( O
28.5 O
) O
62/293 O
( O
21.2 O
) O
Day O
7 O
22/223 O
( O
10.0 O
) O
17/213 O
( O
8.0 O
) O
11/198 O
( O
5.6 O
) O
28/219 O
( O
12.8 O
) O
Day O
30 O
24/223 O
( O
10.8 O
) O
21/211 O
( O
10.0 O
) O
21/199 O
( O
10.6 O
) O
24/224 O
( O
10.7 O
) O
6.2 O
Postmarketing O
Experience O
The O
following O
foreign O
spontaneous O
reports O
have O
been O
identified O
during O
use O
of O
formulations O
similar O
to O
Prepopik O
( O
r O
) O
. O

Because O
these O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Allergic O
reactions O
Cases O
of O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
purpura B-OSE_Labeled_AE
have O
been O
reported O
. O

Electrolyte O
abnormalities O
There O
have O
been O
reports O
of O
hypokalemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
and O
hypermagnesemia B-OSE_Labeled_AE
with O
the O
use O
of O
Prepopik O
( O
r O
) O
for O
colon O
preparation O
prior O
to O
colonoscopy O
. O

Gastrointestinal O
: O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
and O
proctalgia B-OSE_Labeled_AE
have O
been O
reported O
with O
the O
use O
of O
Prepopik O
( O
r O
) O
for O
colon O
preparation O
prior O
to O
colonoscopy O
. O

There O
have O
been O
isolated O
reports O
of O
reversible O
aphthoid O
ileal B-OSE_Labeled_AE
ulcers I-OSE_Labeled_AE
. O

Ischemic B-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
has O
been O
reported O
with O
the O
use O
of O
Prepopik O
( O
r O
) O
for O
colon O
preparation O
prior O
to O
colonoscopy O
. O

However O
, O
a O
causal O
relationship O
between O
these O
ischemic B-NonOSE_AE
colitis I-NonOSE_AE
cases O
and O
the O
use O
of O
Prepopik O
( O
r O
) O
has O
not O
been O
established O
. O

Neurologic O
, O
There O
have O
been O
reports O
of O
generalized B-OSE_Labeled_AE
tonic I-OSE_Labeled_AE
- I-OSE_Labeled_AE
clonic I-OSE_Labeled_AE
seizures I-OSE_Labeled_AE
associated O
with O
and O
without O
hyponatremia B-OSE_Labeled_AE
in O
epileptic B-Not_AE_Candidate
patients I-Not_AE_Candidate
. O

